Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
Disability progression
MOG antibody-associated disorders
Myelin-oligodendrocyte glycoprotein (MOG)
Neuromyelitis optica spectrum disorders
Relapses
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
12
11
2020
revised:
17
12
2020
accepted:
20
12
2020
pubmed:
4
1
2021
medline:
26
5
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
The progression pattern of neurological disability among patients with anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) was evaluated. Neurological disability was evaluated annually for 408 person-years in 50 patients. More than 30% of the patients had clinical relapses in the first 5 years. Disability progression independent of relapse activity (PIRA) was not seen, whereas a stepwise disability progression was observed after clinical attacks in some instances. Disability worsening was more frequent after relapses than after the onset episode (p < 0.01). Similar to patients with anti-aquaporin-4 antibodies, attack-related stepwise disability progression without PIRA is typical in MOGAD, suggesting the importance of relapse prevention.
Identifiants
pubmed: 33388541
pii: S0165-5728(20)30728-1
doi: 10.1016/j.jneuroim.2020.577467
pii:
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
MOG protein, human
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577467Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.